538.84
price up icon1.11%   5.90
after-market Dopo l'orario di chiusura: 538.84
loading
Precedente Chiudi:
$532.94
Aprire:
$534.84
Volume 24 ore:
973.80K
Relative Volume:
2.22
Capitalizzazione di mercato:
$26.84B
Reddito:
$3.17B
Utile/perdita netta:
$1.29B
Rapporto P/E:
19.89
EPS:
27.0947
Flusso di cassa netto:
$1.01B
1 W Prestazione:
+4.08%
1M Prestazione:
-4.41%
6M Prestazione:
+11.02%
1 anno Prestazione:
+79.96%
Intervallo 1D:
Value
$524.58
$541.03
Intervallo di 1 settimana:
Value
$490.80
$541.03
Portata 52W:
Value
$292.34
$609.35

United Therapeutics Corp Stock (UTHR) Company Profile

Name
Nome
United Therapeutics Corp
Name
Telefono
(301) 608-9292
Name
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Name
Dipendente
1,400
Name
Cinguettio
Name
Prossima data di guadagno
2026-08-05
Name
Ultimi documenti SEC
Name
UTHR's Discussions on Twitter

Compare UTHR vs TAK, HLN, TEVA, ZTS

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
UTHR icon
UTHR
United Therapeutics Corp
538.84 26.29B 3.17B 1.29B 1.01B 27.09
TAK icon
TAK
Takeda Pharmaceutical Co Adr
17.45 55.69B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
10.03 43.77B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
35.36 36.19B 17.53B 1.58B 444.18M 1.3457
ZTS icon
ZTS
Zoetis Inc
72.66 32.25B 9.51B 2.64B 2.14B 6.0361

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-04-10 Iniziato Raymond James Outperform
2025-10-20 Iniziato Wells Fargo Underweight
2025-09-26 Iniziato RBC Capital Mkts Outperform
2025-06-02 Iniziato Cantor Fitzgerald Overweight
2025-04-25 Downgrade Wells Fargo Overweight → Equal Weight
2025-04-21 Aggiornamento BofA Securities Underperform → Neutral
2024-07-11 Downgrade Morgan Stanley Overweight → Equal-Weight
2024-02-12 Aggiornamento Goldman Sell → Neutral
2024-02-05 Iniziato Leerink Partners Outperform
2023-12-08 Iniziato Wells Fargo Overweight
2022-12-06 Iniziato UBS Buy
2022-12-05 Iniziato Goldman Sell
2022-10-11 Iniziato Morgan Stanley Overweight
2022-09-20 Reiterato BofA Securities Underperform
2022-09-19 Ripresa Wedbush Outperform
2022-02-11 Iniziato BTIG Research Neutral
2021-07-14 Aggiornamento Argus Hold → Buy
2021-04-26 Ripresa Credit Suisse Outperform
2021-02-01 Aggiornamento H.C. Wainwright Neutral → Buy
2020-09-14 Ripresa JP Morgan Overweight
2020-06-25 Reiterato H.C. Wainwright Neutral
2020-03-10 Aggiornamento Jefferies Hold → Buy
2020-02-27 Aggiornamento Cowen Market Perform → Outperform
2020-01-31 Aggiornamento JP Morgan Neutral → Overweight
2019-12-03 Iniziato BofA/Merrill Underperform
2019-08-01 Aggiornamento Jefferies Underperform → Hold
2019-08-01 Aggiornamento Ladenburg Thalmann Neutral → Buy
2019-07-01 Aggiornamento Credit Suisse Neutral → Outperform
2019-05-17 Aggiornamento UBS Sell → Neutral
2019-05-09 Aggiornamento Credit Suisse Underperform → Neutral
2018-10-12 Aggiornamento Standpoint Research Hold → Buy
2018-08-08 Downgrade Credit Suisse Neutral → Underperform
2018-04-03 Aggiornamento Credit Suisse Underperform → Neutral
2018-02-22 Reiterato Barclays Underweight
2018-01-18 Ripresa Credit Suisse Underperform
2017-12-27 Reiterato Wedbush Outperform
2017-04-27 Reiterato Wedbush Outperform
2017-03-30 Iniziato UBS Sell
2017-03-16 Iniziato Credit Suisse Underperform
Mostra tutto

United Therapeutics Corp Borsa (UTHR) Ultime notizie

pulisher
Jul 27, 2026

United Therapeutics Corp (UTHR) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

United Therapeutics CEO Rothblatt sells $5 million in shares - Investing.com

Jul 27, 2026
pulisher
Jul 27, 2026

United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan

Jul 27, 2026
pulisher
Jul 27, 2026

Form 4 United Therapeutics Corporation For: 27 July By Investing.com - Investing.com Canada

Jul 27, 2026
pulisher
Jul 27, 2026

United Therapeutics CEO Rothblatt sells $5.05 million in stock - Investing.com

Jul 27, 2026
pulisher
Jul 27, 2026

United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise - Stock Titan

Jul 27, 2026
pulisher
Jul 27, 2026

United Therapeutics Corporation (UTHR) Stock Analysis: A Healthier Future with 25.5% Potential Upside - DirectorsTalk Interviews

Jul 27, 2026
pulisher
Jul 27, 2026

United Therapeutics Corp (UTHR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

UTHR|United Therapeutics Corp|Price:528.470|Chg%:-1.060 - TradingKey

Jul 26, 2026
pulisher
Jul 24, 2026

United Therapeutics Corp (NASDAQ: UTHR) CEO trades 9,500 shares in 10b5-1 plan - Stock Titan

Jul 24, 2026
pulisher
Jul 24, 2026

United Therapeutics Corp. (UTHR) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks

Jul 24, 2026
pulisher
Jul 24, 2026

Form 4 United Therapeutics Corporation For: 24 July By Investing.com - Investing.com South Africa

Jul 24, 2026
pulisher
Jul 23, 2026

United Therapeutics Corp. (UTHR) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics Director Christopher Patusky Awarded Stock Options and Common Shares in Annual Equity Grant - Kalkine Media

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics Director Christopher Causey Awarded Stock Options and Common Shares in Annual Equity Compensation - Kalkine Media

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics Director Louis Sullivan Updates Stock Holdings and Receives Annual Stock Option Grant - Kalkine Media

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics Corp. (UTHR) Earnings Dates, Call Summary & Reports - TipRanks

Jul 23, 2026
pulisher
Jul 23, 2026

Form 4 United Therapeutics Corporation For: 23 July By Investing.com - Investing.com South Africa

Jul 23, 2026
pulisher
Jul 23, 2026

Form 4 United Therapeutics Corporation For: 23 July - Investing.com India

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics CEO Rothblatt sells $5 million in shares By Investing.com - Investing.com Canada

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics Corporation (UTHR) Stock Price, News, Quote & History - Yahoo! Finance Canada

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (UTHR) grants director Victor Dzau RSUs and stock options - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (UTHR) director Victor Dzau submits initial Form 3 - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (UTHR) awards RSUs and stock options to director - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics Corp (UTHR) awards RSUs and options to director - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (UTHR) awards director 760 restricted stock units - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (UTHR) awards 760 RSUs to board director Judy D. Olian - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (UTHR) director gets RSU and stock option grants - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (UTHR) awards RSUs and stock options to director Nilda Mesa - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (UTHR) grants director 2,380 stock options at $527.07 - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (UTHR) awards 2,380 stock options to director Causey - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (UTHR) awards 2,380 stock options to board director - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (UTHR) awards 760 RSUs in annual director grant - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (NASDAQ: UTHR) grants stock units and options to director Kurzweil - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics Corp (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics Boosts Board to 13 Members with Appointment of Esteemed Medical Expert Victor Dzau, M.D. - Kalkine Media

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics (NASDAQ: UTHR) appoints Victor Dzau to board - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

After 12 years as NAM president, Victor Dzau joins United Therapeutics board - Stock Titan

Jul 23, 2026
pulisher
Jul 23, 2026

United Therapeutics Corp. (UTH) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks

Jul 23, 2026
pulisher
Jul 22, 2026

United Therapeutics to report Q2 2026 results on August 5 - scanx.trade

Jul 22, 2026
pulisher
Jul 22, 2026

United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026 - Yahoo Finance

Jul 22, 2026
pulisher
Jul 21, 2026

ETFs Investing in United Therapeutics Corporation Stocks - TradingView

Jul 21, 2026
pulisher
Jul 21, 2026

MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits

Jul 21, 2026
pulisher
Jul 21, 2026

Form 4 United Therapeutics Corporation For: 21 July By Investing.com - Investing.com South Africa

Jul 21, 2026
pulisher
Jul 21, 2026

United Therapeutics CEO Rothblatt sells $5.05m in stock By Investing.com - Investing.com Nigeria

Jul 21, 2026
pulisher
Jul 21, 2026

United Therapeutics CEO Rothblatt sells $5.05m in stock - Investing.com

Jul 21, 2026
pulisher
Jul 21, 2026

United Therapeutics (UTHR) CEO executes 9,500-share option exercise and sale - Stock Titan

Jul 21, 2026
pulisher
Jul 21, 2026

Boehringer Alleges United Therapeutics Poached Staff, Secrets - Law360

Jul 21, 2026
pulisher
Jul 20, 2026

United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan

Jul 20, 2026
pulisher
Jul 19, 2026

Lobbying Update: $80,000 of UNITED THERAPEUTICS CORPORATION lobbying was just disclosed - Quiver Quantitative

Jul 19, 2026
pulisher
Jul 17, 2026

United Therapeutics Corp (UTHR) - MSN

Jul 17, 2026

United Therapeutics Corp Azioni (UTHR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

United Therapeutics Corp Azioni (UTHR) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
MAHON PAUL A
EVP & GENERAL COUNSEL
Aug 06 '26
Sale
517.05
8,300
4,291,512
45,172
ROTHBLATT MARTINE A
Chairperson & CEO
Aug 05 '26
Option Exercise
135.42
9,500
1,286,490
333,943
ROTHBLATT MARTINE A
Chairperson & CEO
Aug 05 '26
Sale
518.74
9,500
4,927,985
324,443
ZTS ZTS
$72.66
price down icon 5.97%
$16.43
price up icon 0.86%
$163.41
price up icon 2.25%
$35.36
price up icon 1.58%
$22.12
price down icon 8.60%
Capitalizzazione:     |  Volume (24 ore):